Kim, Moonsik; Yoo, Jihwan; Chang, Jong Hee; Kim, Se Hoon published the artcile< Association of MGMT gene promoter methylation with clinicopathological parameters in patients with wild-type IDH glioblastoma>, Application In Synthesis of 112-63-0, the main research area is isocitrate dehydrogenase MGMT gene promoter methylation clinicopathol glioblastoma human; ATRX loss; MGMT; glioblastoma; hypermethylation; low methylation; methylation status; temozolomide chemotherapy; wild-type IDH.
The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM). The MGMT promoter methylation status and its association with clinicopathol. parameters were retrospectively analyzed in a cohort of 316 patients with GBM with wild-type IDH. MGMT methylation was significantly associated with ATRX chromatin remodeler (ATRX) loss and completion of the standard Stupp protocol. The median durations of overall and progression-free survival for the unmethylated, low-methylated (10-39%), and hypermethylated (≥40%) groups were 15, 23, and 30 mo and 11, 18, and 21 mo, resp. However, the improvement in the survival of the hypermethylated group was not statistically significant. We suggest a possible association between MGMT methylation status and ATRX mutations in GBM with wild-type IDH.
Anticancer Research published new progress about Age groups. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Application In Synthesis of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics